UnitedHealth Group this week became the first major U.S. health insurer to report quarterly earnings, offering a bellwether for the industry’s ability to curb escalating care costs. For the quarter ended December 31, UnitedHealth posted revenue growth of 12.2% year-over-year, delivering $113.16 billion in top-line sales, narrowly below analyst forecasts. Earnings per share came in at $2.92, topping the consensus by $0.05 and reflecting a net margin of 4.04%. The company’s benefit-cost ratio improved by 80 basis points sequentially, driven by lower than expected pharmaceutical inflation and improved hospital utilization trends. Optum, the firm’s services arm, grew revenue by 14.5%, contributing 58% of operating profit, as underlying medical expenses rose at the slowest pace in nearly two years. Management reiterated full-year guidance for mid‐teens top-line growth and EPS near $30, signaling confidence in sustained cost management even as enrollment in Medicaid and Medicare plans expands by over 5% combined during the quarter.

Representative Julie Johnson (D-Texas) disclosed on January 15 that she sold between $1,001 and $15,000 worth of UnitedHealth Group shares from her personal brokerage account on December 18. This transaction marks her first disclosed trade in UNH since assuming office in January 2025. The filing notes the sale occurred in her CHASE BROKERAGE ACCOUNT (3935) and follows a series of comparable dispositions in other large-cap healthcare and industrial names. While such sales fall within regulatory thresholds and do not signal regulatory concerns, they are closely watched by investors given Johnson’s committee assignments overseeing health policy. UnitedHealth’s share register shows that institutional investors control nearly 88% of outstanding stock, leaving only a small free float for insiders, whose moves can influence perceived sentiment on cost trends and regulatory outlooks for Medicare Advantage and Medicaid expansion.